The cost of relapse and the predictors of relapse in the treatment of schizophrenia

by Slade Eric P, Salkever David, Faries Douglas E, Zhu Baojin, Ascher-Svanum Haya, Peng Xiaomei, Conley Robert R
Published 2010-01-01

Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States

by Smolen Lee J, Klein Robert W, Ascher-Svanum Haya, Furiak Nicolas M, Lawson Anthony H, Conley Robert R, Culler Steven D
Published 2009-04-01

Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia

by Ascher-Svanum Haya, Stauffer Virginia, Chen Lei, Ruberg Stephen J, Kollack-Walker Sara, Conley Robert R, Kane John, Kinon Bruce J
Published 2011-02-01